Research
Hormonal
GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) produce clinically significant weight loss (approx. 10-22%) but are associated with high rates of gastrointestinal adverse events.
GLP-1 medications like semaglutide and tirzepatide are highly effective for significant weight loss (10-22%+), but they come with notable gastrointestinal side effects. They are most effective when combined with lifestyle changes and psychological support, rather than used in isolation.
GoodSupportsHIGH confidence
Approximately 37.5% of patients achieve at least a 10% reduction in body mass after two years of treatment... these benefits are accompanied by higher rates of adverse gastrointestinal events, such as constipation, vomiting, and diarrhea.
Why this rating
Based on cited clinical trials and meta-analyses within a narrative review.
Source
Redefining Obesity: A Narrative Review of Diagnostic Evolution, Therapeutic Strategies and Psychosocial Determinants
Artur Przybyłowski et al. · Healthcare · 2025
DOI 10.3390/healthcare13161967
narrative_reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →